Clinical Trial

IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy

Study acronym: IMMUNOLUNG
Recruiting
View on ClinicalTrials.gov →
Summary
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets
Trial Details
NCT Number NCT07608835
Lead Sponsor Institut Paoli-Calmettes
Conditions Non-small Cell Lung Cancer
Enrollment 200 participants
Start Date 2026-02-12
Primary Completion 2033-05-12 (estimated)
Study Completion 2033-05-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27